Bristol Myers Squibb reported two Phase 3 successes on Monday morning, including for an experimental drug that recently ran into safety issues.
A trial testing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.